Mid-Phase Alzheimer’s Failure Sends Neurotrope’s Stock Spiraling Downward
Shares in Neurotrope fell 80% after bryostatin-1 performed no better than placebo in patients with moderate-to-severe Alzheimer’s disease. Neurotrope is yet to officially give up on the protein kinase C epsilon modulator, though.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.